Therapeutic | Onartuzumab |
Target | MET |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIK |
100% seqID Fv Structure | 4k3j [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4k3j [Fvs: HL] |
Follow these links to our prediction tools:
Format | Fab + di-Fc |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2010 |
INN Year Recommended | 2011 |
Companies Involved | Chugai Pharmaceutical, Genentech |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Breast cancer, Colorectal cancer, Gastric cancer, Glioblastoma, Liver cancer, Non-small cell lung cancer, Solid tumours |
Notes |